Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation

Abstract

BACKGROUND

Once daily tacrolimus regimen was found to exhibits similar bioavailability, safety and efficacy properties compared to twice-daily tacrolimus in kidney transplantation patients.

AIM

To compare the efficacy and safety of once-daily prolonged release tacrolimus compared to twice-daily tacrolimus in liver transplantation patients.

METHODS

MEDLINE, EMBASE, CENTRAL databases were searched for clinical trials until December 2020. Efficacy outcome measured as the rate of treatment failure indicated by biopsy-proven acute rejection, Serum creatinine, graft loss, or death. Two reviewers independently selected studies, collected data and assessed risk of bias. The results are reported as risk ratio with 95% confidence interval (CI) for dichotomous data.

RESULTS

Seven studies included with 965 patients. All the included studies were of moderate quality according to the risk of bias assessment using Cochrane Risk of Bias tool. Biopsy-proven acute rejection was reported in four studies, and pooled analysis of those studies indicated similar rejections in both twice daily and once daily tacrolimus groups (risk ratio: 1.06, 95%CI: 0.84-1.34, n = 758, I² = 0%) and also we found no significant difference between both groups for renal outcome (serum creatinine; mean difference, 0.001 mg/dL, 95%CI: -0.042 to 0.043, n = 846, I² = 18.6%). Similarly, there was similar number of adverse events such as hypertension, headache, back pain, blood related disorders, infections and nausea observed in both groups.

CONCLUSION

The analysis findings confirm that both once daily and twice daily tacrolimus formulations are comparable in terms of efficacy and safety outcomes.

Key Words: Prolonged release, Tacrolimus, Liver transplantation, Graft rejection, Renal impairment, FK level

Core Tip: Tacrolimus, a calcineurin inhibitor is an important component of the immunosuppressive regimens post liver transplantation. Compliance to immuno-suppression treatment generally is important and non-adherence is a major risk factor of graft rejection and loss. Compliance to medication declines over the course of time in patients after liver transplantation due to several factors and this contributes to about 20% of late acute rejection. The efficacy of once daily tacrolimus regimens has been reported in many studies and this systematic review/meta-analysis confirmed the evidence of comparable efficacy and safety of prolonged release tacrolimus to the twice daily immediate release formulation.

INTRODUCTION

Advances in immunosuppression regimens after solid-organ transplantation have significantly improved patient and graft survival. Tacrolimus, a calcineurin inhibitor is an important component of the immunosuppressive regimens widely used following liver transplantation (LT). Compliance to immunosuppression treatment however is important and non-adherence is a recognized contributing factor in rejection and graft loss[1,2].

Compliance to medication declines over the course of time in patients after LT due to several factors including the number of drugs to consume and the rate of rejection/infections increases. Previous reviews directed at recipients transplanted between the late 1980s and mid-2000s showed that the prevalence of non-adherence to immunosuppressive medications averaged about 25%. This non-adherence to medications was felt to contribute to about 20% of late acute rejection episodes and 16%-36% of graft losses[3]. To maintain good adherence, less frequently administering regimen were proved to be effective[4].

Recently, tacrolimus once-daily prolonged-release (PR) formulation was developed. Based on the previous literature, it was evident that conversion from the twice-daily, immediate release (IR) to PR tacrolimus was well tolerated, safe and conveniently used in stable patients after LT[5,6]. However, there is no systematic review that has been conducted till date to confirm the efficacy and safety of PR tacrolimus compared to IR tacrolimus.

MATERIALS AND METHODS

Database search

This systematic review and meta-analysis was performed according to Cochrane Collaboration[7] and Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement[8].

We searched MEDLINE, EMBASE, CENTRAL databases since inception to December 2020 using an extensive search strategy to identify relevant literature. We used the following terms: Tacrolimus, liver transplantation and dosage forms (Supplementary file) while searching databases with human and English language restrictions. In addition, we also searched clinicaltrials.gov.in and Google Scholar and references of previously published relevant papers to find more relevant trials.

Eligibility criteria

Clinical trials conducted on adult (> 18 years) patients who received a primary LT from a deceased or living donor, having an average serum tacrolimus level of 1-10 ng/mL for more than 6 wk, that compared once daily tacrolimus to twice daily tacrolimus in LT patients were included.

Exclusion criteria

Studies were excluded if they had patients with a previous organ transplant other than liver and multiple organ transplantations. Studies also conducted on paediatric population and lack of a control group (the study had only included patients who received once daily tacrolimus. We also excluded studies only assessed pharmacokinetics of tacrolimus. Finally, studies without full-text such as conference proceedings, editorials, reviews, secondary analyses and letters excluded.

Outcomes: Efficacy was measured as the rate of treatment failure indicated by biopsy-proven acute rejection (BPAR), liver graft loss, or death while safety was assessed by the incidence of adverse events.

Study selection and data extraction

Two reviewers independently (KB and RT) screened the identified studies according to the aforementioned criteria and excluded studies that were found to be clearly irrelevant. We obtained the full text of the remaining studies and the same two reviewers screened full texts and selected trials for inclusion. The same two reviewers independently extracted data from included trials into the predesigned and validated data collection form. Disagreements were resolved by arbitration, and consensus was reached after discussion. We collected study characteristics (type of design with duration of intervention and methods), baseline demographics, and efficacy and safety outcome data from each included trial.

Quality assessment

Two reviewers (KB and RT) independently assessed quality of included studies using Cochrane Risk of Bias tool[9], and disagreements were resolved by discussion. If a consensus could not be reached, any discrepancy was resolved by a senior author. Seven domains of quality assessment included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias.

Statistical analysis

We performed statistical analysis using Comprehensive Meta-analysis Version 3.0[10]. We reported the results as risk ratio with 95% confidence interval (CI) for dichotomous data and continuous data as mean difference. We used a random-effects model to combine individual results regardless whether there was significant heterogeneity or not. We tested heterogeneity among trial results using the I² statistic[7]. We considered a value greater than 50% as substantial heterogeneity. Publication bias was not assessed due to limited number of included studies in this review.

RESULTS

A total of 701 articles from databases search and 15 from additional searches identified. After removing duplicates 543 studies remained for screening. Upon screening titles and abstracts, 490 clearly irrelevant articles removed. The remaining 48 articles subjected to full text screening. Finally, seven clinical trials met the inclusion criteria[11-17]. The flow of the randomised controlled trial included in our analysis is shown in Figure 1.

Figure 1 Preferred reporting items for systematic reviews and meta-analyses flow chart.

Study characteristics

A total of seven clinical trials were included with 965 patients. Study characteristics were summarized in Table 1. Studies included are conducted in various countries including United States, Japan, United Kingdom, and one study in another 16 countries.

Table 1 Characteristics of the included studies.

Ref.	Year	Country	Study design	Follow-up period	Sample size	Donor type	Mean age	Concurrent therapy
Alloway et al[11]	2014	United States	Phase-II, 3-sequence, open-label, multicenter, prospective study	1 yr	59	NR	49.8	Mycophenolate mofetil
Kim et al[13]	2016	South Korea	2-armed, parallel group, prospective, randomized, open-label, phase IV	1 yr	79	Deceased	54	NR
Sańko-Resmer et al[14]	2012	United Kingdom	Multicentre, open-label, single-sequence, crossover, phase IIIb	3 mo	98	NR	55	None
Shin et al[17]	2018	South Korea	Phase IV, randomized, open-label, comparative, single-center study	6 mo	100	NR	52	Corticosteroid, mycophenolate mofetil, and basiliximab.
Trunečka et al[15]	2010	16 countries	1:1-randomized, double-blind, double-dummy, two-arm, parallel-group phase III, comparative study	1 yr	471	NR	52	Mycophenolate sodium
DuBay et al[12]	2019	United States	Phase II, open label, multicenter, randomized trial	1 yr	29	Deceased	54.4	Mycophenolate mofetil, mycophenolic acid sodium, prednisone, or azathioprine
Fischer et al[16]	2010	Germany	Randomized, phase II, multicenter, open-label, prospective trial	6 wk	129	NR	47	Anti-fungal, antibiotics, anti-hypertensives, antiepileptics and rifampicin)

NR: Not reported.

The mean age of included patients was 52.8 years and majority (71%) of them were males. Four studies had follow-up for one year while the other two had follow up for 3 and 6 mo. In four studies, concomitant treatment with mycophenolate mofetil and steroids was allowed. All the included studies were of moderate quality according to the risk of bias assessment using Cochrane Risk of Bias tool (Figure 2).

Figure 2 Risk of bias assessment according to Cochrane risk of bias tool.

Efficacy outcomes

Acute rejection confirmed by biopsy was reported in four studies[12,15-17], and pooled analysis of those studies indicated similar rejection rate in both twice daily and once daily tacrolimus groups (risk ratio 1.06, 95%CI: 0.84-1.34, n = 758, I² = 0%; Figure 3).

Figure 3 Efficacy outcomes. A: Acute graft rejection; B: Infection; C: Any adverse drug reaction; D: Headache; E: Back pain; and F: Blood disorders. CI: Confidence interval.

DISCUSSION

This systematic review and meta-analysis compared PR tacrolimus to IR tacrolimus in LT recipients. The efficacy and safety outcomes were found to be similar for both regimens.

Adherence to the immunosuppressant regimen post-LT is important for preventing rejection and graft loss. The reported rate of non-adherence to immunosuppressant regimens is 15%-40%, which could lead to significantly higher rate of graft rejection, graft loss and severe impact on long-term survival[18]. It was observed that once daily tacrolimus is safe and is associated with better adherence and low variability of liver function tests[18,19].

A study by Muduma et al[20] looked at the cost effectiveness of PR tacrolimus in LT recipients. Based on a United Kingdom specific analysis of the projected cost-utility of PR tacrolimus relative to IR tacrolimus and cyclosporin, once daily tacrolimus was cost-effective, improved life expectancy and quality adjusted life year and incremental cost effectiveness ratio below £20000 per a quality adjusted life year gained. Over a 3-year time horizon, one graft would be saved for every 14 patients treated with PR tacrolimus with minimal impact on cost when compared to IR tacrolimus.

The results of recently published systematic review showed that PR tacrolimus when compared to the IR tacrolimus resulted in no significant difference in the glomerular filtration rate, BPAR and the safety outcomes among the kidney transplant recipients[21]. The findings of our review are also in congruent with the previous review. In contrast, another meta-analysis based on combination of two clinical trials and four observational studies found that once daily tacrolimus is effective for the first year after liver transplantation, however, there was no significant difference in 1-year mortality and adverse events between once daily and twice daily tacrolimus groups[22].

PR tacrolimus has been introduced as helpful therapeutic option to increase the patient adherence to immunosuppressive treatment. Studies with short follow-up and pharmacokinetic evaluation were not included in this review, however one study which evaluated pharmacokinetic outcomes along with efficacy outcomes showed similar BPAR, graft losses and safety outcomes such as hypertension, infections and blood related disorders[16] between groups. Of the included studies in our systematic review, four reported concomitant immunosuppressant therapies administration such as corticosteroids, and mycophenolate mofetil. It was evident that those concomitant drugs have negative association with occurred adverse events with tacrolimus[23]. An eight years long-term follow up study based on European Liver Transplant Registry has recently been published study and the findings were in favour of PR in terms of graft losses and acute rejections. This very large population study also reported better outcome in those converted from IR to PR tacrolimus after 1 mo compared to those maintained on IR tacrolimus-based immunosuppression. They concluded that patients on PR tacrolimus continues to provide ongoing benefits for graft and patient survival beyond 3 years post transplantation[24]. The major limitation of the study, were the lack of data on the dosages and the trough levels of tacrolimus were not captured. In addition, the lack of clarity on the IR tacrolimus preparations the cohort received. The retrospective design of the study was the main reason for its exclusion in our analyses as it did not meet the eligibility criteria.

Strengths and limitations

The major strength of our study is that, we have only included clinical trials of long-term follow-up to address efficacy and safety of PR tacrolimus. There was no heterogeneity found for all the outcomes assessed, except for any adverse events. One of the limitations of our review is that, we have only included studies published in English language, which means some of the studies published in other language might have been missed. Publication bias assessment was also not assessed due to less than ten studies included in the analysis, however due to our intense search effort it was evident that we did not miss any study meeting this review’s eligibility criteria. Majority of the studies were of open-label design, that could have introduced bias, however this could not be avoided due to the nature of administration. In addition, the paucity of studies of PR tacrolimus in Asian patients renders data from this review of high interest to the transplant community.

CONCLUSION

Our systematic review and meta-analysis indicate that both PR and IR tacrolimus formulations are comparable in terms of efficacy and safety outcomes. However, to confirm these findings, long-term follow-up randomized controlled trials with large sample sizes are required. Also, to assess acceptability by patients, quality of life and economic evaluations should be conducted.

ARTICLE HIGHLIGHTS

Research background

Tacrolimus, a calcineurin inhibitor is an important immunosuppressive medication post liver transplantation. Compliance to immunosuppression is important and non-adherence can lead to rejection and graft loss. To maintain good adherence, less frequently administering regimen were proved to be effective.

Research motivation

Recently, tacrolimus once-daily prolonged-release (PR) formulation was developed. Several studies have shown evidence that conversion from the twice-daily, immediate release to PR tacrolimus was well tolerated, safe and conveniently used in stable patients after liver transplantation.

Research objectives

Our objective was to conduct a metanalysis and systematic review of the published clinical trials that studied the safety and efficacy of PR tacrolimus compared to immediate release tacrolimus.

Research methods

MEDLINE, EMBASE, CENTRAL databases were searched for clinical trials until December 2020. Efficacy outcome measured as the rate of treatment failure indicated by biopsy-proven acute rejection, Serum creatinine, graft loss, or death. Two reviewers independently selected studies, collected data and assessed risk of bias. The results are reported as risk ratio with 95%CI for dichotomous data.

Research results

Seven studies included with 965 patients. All the included studies were of moderate quality according to the risk of bias assessment using Cochrane Risk of Bias tool. Biopsy-proven acute rejection was reported in four studies, and pooled analysis of those studies indicated similar rejections in both twice daily and once daily tacrolimus groups. We also found no significant difference between both groups for renal outcome (serum creatinine; mean difference, 0.001 mg/dL, 95%CI: -0.042 to 0.043, n = 846, I² = 18.6%). Similarly, there was similar number of adverse events such as hypertension, headache, back pain, blood related disorders, infections and nausea observed in both groups.

Research conclusions

The analysis findings confirm that both once daily and twice daily tacrolimus formulations are comparable in terms of efficacy and safety outcomes.

Research perspectives

Long-term follow-up randomized controlled trials with large sample sizes are required. Also, to assess acceptability by patients, quality of life and economic evaluations should be conducted.